Treatment of Transcranial Alternating Current Stimulation（tACS）on

Status Recruiting

Clinical Trial Summary

This is a longitudinal, triple-blind, randomized-controlled, prospective observational study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type (MSA-C), to examine the efficacy, safety, and tolerability of transcranial alternating current stimulation (tACS) for up to 3 months.

Clinical Trial Description

Transcranial alternating current stimulation (tACS) is a relatively recent method that noninvasively modulates brain oscillations, and can effectively stimulate deep brain regions, affect brain rhythm, increase neural plasticity, change neurotransmitter levels, and improve brain function. It is a comfortable, safe, effective, non-invasive, and easy-to-operate method, which means it has development potential in relevant medical fields. It has been approved by the FDA for clinically treating neuropsychiatric diseases. This is a prospective, longitudinal, triple-blind, randomized-controlled, observational study designed to evaluate the efficacy, safety, and tolerability of tACS in patients of SCA3 and MSA-C in China. Based on typical guidelines, we will use the tACS paradigm (bilateral mandible as a place for active electrode stimulation electrode, and the inion for the return electrode). Subjects will be randomized into two groups, one receiving a 10-day (5 days/week for 2 weeks) treatment with real cerebellar tACS and the other receiving a sham stimulation. The patient's motor function, cognitive function, sleep, mental state, plantar pressure, electroencephalogram, and magnetic resonance imaging will be assessed before and after the intervention. There will be a total of 4 visits. All patients receiving CB-tACS will be visited face to face at baseline, day 1, day 30, and day 90 after the treatment begins. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05557786
Study type	Observational
Source	First Affiliated Hospital of Fujian Medical University
Contact	Shi-Rui Gan, MD, PhD
Phone	0591-87982772
Email	ganshirui@fjmu.edu.cn
Status	Recruiting
Phase
Start date	August 1, 2022
Completion date	March 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00992771` - Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3	Phase 2
Completed	`NCT01096082` - Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3	Phase 2/Phase 3
Active, not recruiting	`NCT03701399` - Troriluzole in Adult Subjects With Spinocerebellar Ataxia	Phase 3
Active, not recruiting	`NCT04229823` - Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
Active, not recruiting	`NCT04419974` - Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
Terminated	`NCT05490563` - STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia	Phase 2/Phase 3
Withdrawn	`NCT04301284` - Study of CAD-1883 for Spinocerebellar Ataxia	Phase 2
Withdrawn	`NCT01096095` - Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3	Phase 2
Active, not recruiting	`NCT04268147` - Instrumented Data Exchange for Ataxia Study
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Active, not recruiting	`NCT05826171` - Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia	N/A
Recruiting	`NCT04399265` - Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3	N/A
Completed	`NCT03885167` - Identification of Biomarkers in Spinocerebellar Ataxia 3
Terminated	`NCT05160558` - A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3	Phase 1
Recruiting	`NCT05822908` - A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD	Phase 1/Phase 2
Not yet recruiting	`NCT03378414` - Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia	Phase 2
Completed	`NCT05502432` - Repetitive Transcranial Magnetic Stimulation in SCA3 Patients	N/A
Recruiting	`NCT04714307` - Neuropsychiatry and Cognition in SCA3/MJD
Recruiting	`NCT01060371` - Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treatment of Transcranial Alternating Current Stimulation（tACS）on Cerebellar Ataxia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms